A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer
Imugene Limited
Imugene Limited
Suzhou Genhouse Bio Co., Ltd.
Chang Gung Memorial Hospital
European Institute of Oncology
Henan Cancer Hospital
University Hospital, Antwerp
Nantes University Hospital
Centre Hospitalier Universitaire Vaudois
Universitair Ziekenhuis Brussel
Palobiofarma SL
Centre Hospitalier Universitaire de Liege
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Aurigene Discovery Technologies Limited
University Hospital Ostrava
Assistance Publique - Hôpitaux de Paris
Radiotherapy Oncology Centre "Santa Maria" Hospital
The Central Hospital of Lishui City
Zhejiang Cancer Hospital
University of Milano Bicocca
Hunan Province Tumor Hospital
Beijing Tsinghua Chang Gung Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
The First Affiliated Hospital of Xinxiang Medical College
Loyola University
IRCCS San Raffaele
Royal College of Surgeons, Ireland
The Third Affiliated hospital of Zhejiang Chinese Medical University
Huashan Hospital
University of Kansas Medical Center
The University of Queensland
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Sanguine Biosciences
Second Affiliated Hospital of Nanchang University
Qianfoshan Hospital
Vastra Gotaland Region
Vestre Viken Hospital Trust
Beijing Biostar Pharmaceuticals Co., Ltd.
University of Kansas Medical Center
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
OncoResponse, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Massachusetts General Hospital
Centre Georges Francois Leclerc
University of Manchester